Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOcugen Inc

Ocugen Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.925 USD 0.11 ( 13.29%)
Last update at 2026-11-06T21:22:00Z
VOLUME
7413912
Market Cap
440.08M

Momentum Score

…

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.82
Low
0.97
High
52 Week Price Range
0.34
Low
2.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ocugen Inc is a clinical-stage biopharmaceutical company developing gene therapies and biologics for rare inherited retinal and other ocular diseases. Long-term growth drivers include clinical progress of lead programs, potential regulatory approvals and partnerships, and expansion of its ocular therapy platform, which may benefit from unmet needs in small-market ophthalmic indications.

Material risks include clinical and regulatory failure, significant cash burn with likely need for additional financing and dilution, and competition and execution challenges in developing and commercializing niche ophthalmic therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.82
Dividend Yield
-
Revenue TTM
6.61M
Revenue Per Share
0.03
Gross Profit TTM
-49.76M
Debt / Equity
0.17
ROE
-108.76%
Net Debt
-32.52M
ROCE
-179.84%
Diluted EPS TTM
-0.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -81.35M -58.42M -21.82M -20.24M -8.64M
Net income -77.83M -58.37M -22.62M -21.23M -8.64M
Selling general administrative 35.11M 22.92M 7.97M 6.08M 10.20M
Gross profit - - 0.04M - -
Reconciled depreciation 0.48M 0.23M 0.10M 0.06M 0.45M
Ebit -85.35M -58.03M -21.28M -14.16M -42.17M
Ebitda -84.87M -58.34M -14.10M -14.89M -41.72M
Depreciation and amortization 0.48M -0.31M 7.18M -0.72M 0.45M
Non operating income net other - -0.31M 0.18M -4.31M -
Operating income -84.87M -58.03M -21.28M -14.16M -30.11M
Other operating expenses 84.87M 58.03M 14.33M 14.16M 25.84M
Interest expense 3.52M 0.08M 0.72M 1.77M 0.16M
Tax provision 0.00M -0.05M - - -
Interest income - - 0.00M 0.00M 20.03M
Net interest income - -0.08M -0.72M -1.77M -0.57M
Non recurring - - 7.00M - -
Income tax expense -4.00M -0.05M 0.80M 0.98M -15.76M
Total revenue 0.00M 0.02M 0.04M 0.00M 0.00M
Total operating expenses 84.87M 58.03M 14.33M 14.16M 25.84M
Total other income expense net 3.52M -0.39M -0.54M -6.08M 17.77M
Net income from continuing ops -81.35M -58.37M -21.82M -20.24M -8.64M
Net income applicable to common shares -81.35M -58.37M -34.37M -20.24M -18.22M
Preferred stock and other adjustments - - 12.55M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 64.55M 108.63M 105.76M 27.38M 16.81M
Other current assets 3.51M 7.56M 7.69M 1838.36M 8322.17M
Total liab 23.98M 24.58M 9.94M 5.83M 5.79M
Total stockholder equity 40.56M 84.05M 95.82M 21.55M 11.02M
Other current liab 2.82M 9.90M 0.29M 0.01M 0.21M
Common stock 2.57M 2.22M 2.00M 1.84M 0.53M
Capital stock 2.57M 2.22M 2.00M 1.84M 0.53M
Retained earnings -286.17M -213.02M -131.67M -73.30M -51.48M
Other liab - 0.24M - - 0.00M
Other assets - 0.18M 1.95M 0.43M 0.47M
Cash 39.46M 77.56M 94.96M 24.04M 7.44M
Total current liabilities 17.09M 18.46M 7.00M 3.61M 4.54M
Current deferred revenue 10.53M - 4.03M 2.93M 2.27M
Net debt -32.52M -71.19M -91.65M -21.55M -6.04M
Short term debt 0.57M 0.50M 0.36M 0.28M 0.17M
Short long term debt - - - 0.23M -
Short long term debt total 6.94M 6.37M 3.31M 2.49M 1.41M
Other stockholder equity 324.14M 294.83M 225.49M 93.01M 61.97M
Property plant equipment - 9.96M 1.16M 1.07M 0.22M
Total current assets 42.97M 98.49M 102.65M 25.88M 15.77M
Net tangible assets - 84.05M 95.82M 21.55M 11.02M
Short term investments 0.00M 13.37M - - -
Net receivables - - 4.99M - -
Long term debt 2.80M 2.29M 1.71M 1.82M 1.07M
Inventory - - 4.99M - -
Accounts payable 3.17M 8.06M 2.31M 0.40M 1.90M
Accumulated other comprehensive income 0.02M 0.03M - - -
Common stock total equity - - 2.00M 1.84M 0.53M
Preferred stock total equity - - 0.00M - -
Retained earnings total equity - - -131.67M -73.30M 51.48M
Treasury stock - - -0.05M -0.05M -0.05M
Non currrent assets other 3.37M 4.09M 1.95M 0.87M 0.82M
Non current assets total 21.58M 10.14M 3.12M 1.50M 1.04M
Capital lease obligations 4.14M 4.08M 1.59M 0.43M 0.34M
Long term debt total - - 1.71M 1.82M 1.07M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -16.97M -1.82M -0.31M -2.33M -1.11M
Change to liabilities 9.49M 3.50M -0.54M -1.88M 3.63M
Total cashflows from investing activities -16.97M -1.82M -0.31M -2.36M -0.08M
Net borrowings 0.50M -0.01M -4.73M 5.29M 7.29M
Total cash from financing activities 59.48M 120.68M 31.61M 25.07M 25.35M
Change to operating activities -0.29M -1.01M -0.67M -1.48M -0.25M
Net income -81.35M -58.37M -21.82M -20.24M -8.64M
Change in cash -17.55M 70.92M 16.60M 5.82M 8.46M
Begin period cash flow 95.11M 24.19M 7.60M 1.78M 7.22M
End period cash flow 77.56M 95.11M 24.19M 7.60M 15.68M
Total cash from operating activities -60.08M -47.94M -14.71M -16.89M -15.78M
Issuance of capital stock 59.57M 129.21M 37.82M 22.73M 25.53M
Depreciation 0.48M 0.23M 0.10M 0.06M 0.45M
Other cashflows from investing activities 0.76M -0.75M -0.75M -2.33M 0.90M
Dividends paid - - - 6.80M -
Sale purchase of stock - 120.69M 36.34M -0.05M 25.53M
Other cashflows from financing activities -0.09M -8.53M -0.56M 14.50M 0.00M
Change to netincome 11.60M 7.71M 8.22M 5.81M 3.16M
Capital expenditures 4.46M 0.94M 0.31M 0.03M 2.01M
Cash flows other operating - -0.33M -0.28M -0.64M -
Cash and cash equivalents changes - 70.92M 16.60M 5.82M -
Change in working capital 9.20M 2.49M -1.21M -3.11M -2.81M
Stock based compensation 10.54M 6.96M 0.66M 0.88M 1.62M
Other non cash items 1.06M 0.80M 7.56M 2.33M 10.73M
Free cash flow -64.54M -48.88M -15.02M -16.92M -17.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OCGN
Ocugen Inc		 0.11
13.29%		 0.93 - 15.22 25069.32 7.51 35591.28 -4.88
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

263 Great Valley Parkway, Malvern, PA, United States, 19355

484 328 4701

https://www.ocugen.com

65

Name Title Year Born
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. Co-Founder, Chairman & CEO 1964
Dr. Uday B. Kompella Ph.D. Co-founder & Independent Director 1967
Dr. Vijay Tammara Ph.D. Sr. VP of Regulatory & Quality 1960
Ms. Jessica Crespo CPA, CPA Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer 1977
Dr. Arun Upadhyay Ph.D. Chief Scientific Officer NA
Ms. Tiffany Hamilton M.B.A. Head of Corp. Communications NA
Ms. Zara Gaudioso AVP, Head of HR & Chief of Staff NA
Mr. Michael Shine Sr. VP of Commercial NA
Dr. Robert J. Hopkins FACP, M.D., M.P.H. Chief Medical Officer NA
Dr. Shankar Musunuri M.B.A., Ph.D. Co-Founder, CEO & Chairman 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…